Microscopic Polyangiitis

This is a rare type of inflammation that affects small blood vessels in your body, mainly in the kidneys and lungs. It's often linked to certain antibodies your body makes. Doctors diagnose it based on symptoms and blood tests.

Condition

What people with Microscopic Polyangiitis report

Every report comes from a Lived member, sent anonymously.

Have you tried Rituximab for Microscopic Polyangiitis?

NameHow it went

About Microscopic Polyangiitis

What It Is

Microscopic polyangiitis (MPA) is a rare autoimmune disease in which the immune system attacks the walls of small blood vessels. The inflamed vessels can narrow, leak or close off, which starves the tissue they supply. Because small vessels run through every organ, MPA can affect many parts of the body at once, but it most often damages the kidneys, the nerves of the arms and legs, the skin and the lungs. Many people first feel generally unwell for weeks or months, with fatigue, fever, aches and weight loss, before organ-specific problems appear. Kidney inflammation (glomerulonephritis) is the most common and most consequential feature, and it can progress without obvious symptoms. Other signs include a purple, raised rash on the lower legs, numbness or weakness in a hand or foot, and coughing up blood when the lungs are involved. Most people with MPA have antineutrophil cytoplasmic antibodies (ANCA), immune proteins aimed at their own white blood cells, so MPA is grouped with similar diseases as ANCA-associated vasculitis. Its closest relative is granulomatosis with polyangiitis (GPA), which more often affects the nose and sinuses. The two are treated in much the same way. Without treatment MPA can cause kidney failure and life-threatening lung bleeding, which is why early diagnosis matters.

Causes & Risk Factors

The exact cause of MPA is not known. It arises from a mix of genetic susceptibility and something in a person's environment that sets off an abnormal immune response. In most people, no single trigger can be identified. Age is the clearest risk factor: MPA can occur at any age, but it becomes more common later in life, with onset often in the 60s and 70s. It is somewhat more common in men, and MPA is more common than GPA in people of East Asian descent. Researchers have linked certain immune gene variants to MPA, but these do not determine who will develop it. Some exposures are associated with higher risk. These include years of inhaling silica dust (in mining, stonework, construction and similar trades), and some medicines, notably hydralazine (a blood pressure drug), propylthiouracil (a thyroid drug) and minocycline (an antibiotic). Cocaine contaminated with levamisole can cause a similar vasculitis. When a medicine or drug is the likely trigger, stopping it is part of treatment. Infections may also play a role in starting the disease or prompting flares.

How It's Diagnosed

There is no single test for MPA. Doctors put the diagnosis together from symptoms, examination, blood and urine tests, imaging and, usually, a biopsy. The ANCA blood test looks for the antibodies typical of this group of diseases. In MPA they are usually directed against an enzyme called myeloperoxidase (MPO-ANCA). A positive result supports the diagnosis but does not prove it on its own, and a small share of people with MPA test negative. Markers of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are often high, though they rise with many other illnesses too. Kidney tests are central. A urine test that shows blood, protein or clumps of red blood cells (casts) points to inflamed kidney filters, and blood creatinine shows how well the kidneys are working. A chest computed tomography (CT) scan can reveal lung involvement, and nerve conduction studies can map nerve damage. A biopsy, most often of the kidney, sometimes of skin, nerve, muscle or lung, usually confirms the diagnosis by showing inflamed small vessels with few antibody deposits. It also helps rule out look-alikes such as infection, other forms of vasculitis and other kidney diseases, which can need very different treatment.

Treatment Options

Treatment works in two phases. The first, called induction, aims to switch off the inflammation quickly, ideally within a few months, to protect the kidneys, lungs and nerves. The second, called maintenance, aims to keep the disease in remission and prevent relapses. For induction, most people receive either rituximab (Rituxan, or a biosimilar such as Truxima, Ruxience or Riabni) or cyclophosphamide. Rituximab is an antibody infusion that removes the B cells that make ANCA; cyclophosphamide is an older immunosuppressive drug given as intravenous pulses. In trials the two worked about equally well for new disease. Rituximab is generally preferred for a relapse, and it avoids cyclophosphamide's longer-term risks, which include bladder and other cancers. People with milder disease that does not threaten an organ are sometimes treated with methotrexate or mycophenolate instead. Glucocorticoids (steroids such as prednisone) are given alongside, starting high and tapering. Trials have shown that a faster, lower-dose taper works as well as older high-dose schedules and causes fewer serious infections. Avacopan (Tavneos), a capsule that blocks part of the immune complement system, can be added to cut the amount of steroid needed. It reduced steroid side effects in its main trial, and it requires regular liver blood tests. Plasma exchange, which filters antibodies from the blood, may be considered for people with severe kidney failure at diagnosis, weighing a better chance of avoiding dialysis against a higher risk of infection. Once the disease is controlled, maintenance treatment usually continues for about two to four years. Rituximab infusions every four to six months prevent relapses better than azathioprine tablets, which, like methotrexate, remain an alternative. How long to continue depends on relapse risk, infection risk and personal preference. Because these medicines weaken the immune system, care also includes protection against infection: often an antibiotic such as co-trimoxazole (Bactrim) to prevent a serious pneumonia, recommended vaccines (live vaccines are usually avoided), and checks for hepatitis B before rituximab. Bone protection is often added while on steroids. If the kidneys fail, dialysis and later a kidney transplant are options, usually once the disease has been in stable remission for six to twelve months.

What to Expect

Treatment usually brings the disease under control within about four to six months, after which the focus shifts to keeping it quiet. MPA is still a long-term condition, though. The first months are usually the most demanding, with frequent appointments, infusions or tablets, blood and urine tests, and the fatigue and side effects that come with high-dose steroids. Some effects can last after the inflammation has settled. Kidney function lost before treatment may not fully come back, and about a fifth to a quarter of people with MPA or GPA reach kidney failure within a few years of diagnosis and need dialysis or a transplant. Nerve damage can leave lasting numbness, weakness, muscle wasting or foot drop. Relapses can happen, so follow-up continues long after the first treatment phase ends. Regular urine tests matter because kidney inflammation can return before any symptoms appear. Over the long run, people with MPA have a higher risk of infections, heart and blood vessel disease and some cancers, so blood pressure, cholesterol, vaccinations and recommended cancer screening deserve attention. Care is often shared between a rheumatologist or kidney specialist and other teams, and patient groups such as the Vasculitis Foundation can help with information and support.

When to Seek Help

See a doctor if you have weeks of unexplained fatigue, fever or weight loss together with a leg rash, numbness or weakness in a hand or foot, joint pain or blood in the urine, especially if a routine urine test has shown blood or protein. These can be early clues to vasculitis. If you already have MPA, contact your care team right away about dark or bloody urine, new swelling in the legs, symptoms that return or new ones that appear, and any fever or other sign of infection while you are on immunosuppressive treatment. Coughing up blood, or breathlessness that comes on or worsens quickly, can mean bleeding into the lungs, which can quickly become life-threatening. Get emergency care for these symptoms.

Questions to Ask Your Doctor

  1. 1.Which organs are affected in my case, and how will we track my kidney function over time?
  2. 2.Why do you recommend rituximab or cyclophosphamide for me, and how will my steroid dose be reduced?
  3. 3.What will maintenance treatment involve, and how will we decide when it is safe to stop?
  4. 4.What should I do to lower my infection risk, and which vaccines should I have?
  5. 5.Which symptoms should make me suspect a relapse, and how quickly should I call you?

Last reviewed • Oct 2026

Educational content, not medical advice.